UK-BCM-240035. DOP: April 2024.
Resources
BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5
Prescribing information and adverse event reporting can be found using the link above.
For healthcare professionals
BOTOX® Injection Site Anatomy Poster with Muscles and Nerves
This poster shows a summary of the PREEMPT treatment paradigm, a culmination of over 10 years’ experience of migraine research, optimised to help patients with chronic migraine maximise their likelihood of a beneficial effect.
To receive a copy of this poster, please submit your details on the Contact Us page and tick BOTOX® Injection Site Anatomy Poster with Muscles and Nerves.
BOTOX® dosage and administration guide
This guide provides a summary of the dosage and administration for BOTOX® and offers additional useful information on contraindications, injection sites, and recommended treatment intervals.
To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® dosage and administration guide.
Educational resources for healthcare professionals
BOTOX® (botulinum toxin type A) for the management of chronic migraine
These educational modules have been developed to support healthcare professionals who manage patients with CM.
These modules are designed to be used at peer-to-peer meetings, presented either by a healthcare professional or by an AbbVie Key Account Manager. If you are interested in discussing these modules further, please submit your details on the Contact us page. Tick the appropriate box which relates to the module(s) in which you are interested and a member of the AbbVie team will be in contact with you.
Chronic migraine overview, prevalence and burden
- An overview of the prevalence and characteristics of chronic migraine
- An overview of the symptoms, risk factors and comorbidities associated with chronic migraine
- The impact of chronic migraine on patients’ quality of life
Ensuring an accurate diagnosis of chronic migraine
- A review of the criteria for a chronic migraine diagnosis
- The key steps required to accurately diagnose chronic migraine
- An overview of the considerations for diagnosing chronic migraine, including patient history
Treatment options and management
- An overview of the different approaches to managing chronic migraine
- A review of the risks associated with acute medication overuse and how to manage medication overuse headache
- Prophylactic treatment options for chronic migraine
Pathophysiology of chronic migraine and mechanism of action of BOTOX®
- The processes leading to central sensitisation in chronic migraine
- An overview of what BOTOX® is and how BOTOX® works
Efficacy and safety of BOTOX® in chronic migraine
- The efficacy and tolerability of BOTOX® for chronic migraine
- A review of the results from clinical studies in chronic migraine, including the Phase III PREEMPT clinical programme and the COMPEL clinical study
- A review of real-world evidence supporting the use of BOTOX® injection for the treatment of chronic migraine
The BOTOX® injection procedure in chronic migraine
- Reconstitution protocols for BOTOX® for chronic migraine injection
- BOTOX® injection technical protocols, including an overview of the BOTOX® PREEMPT injection paradigm
- A review of considerations for before, during and after the BOTOX® injection procedure
The BOTOX® injection procedure in chronic migraine
- Reconstitution protocols for BOTOX® for chronic migraine injection
- BOTOX® injection technical protocols, including an overview of the BOTOX® PREEMPT injection paradigm
- A review of considerations for before, during and after the BOTOX® injection procedure
Resources for your patients
Patient Guide for the Treatment of Chronic Migraine with BOTOX®
To support your chronic migraine patients treated with BOTOX®, this guide provides information on how the treatment works, what to expect during and after treatment and potential side-effects.
The information in this guide does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.
To receive a copy of this guide, please submit your details on the Contact Us page and tick Chronic Migraine Patient Guide.
CM: chronic migraine; GIRFT: Getting It Right First Time.
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
Date of preparation: March 2024. UK-BCM-240052.
